Cart
sales@molnova.com
Amlexanox
CAS No. 68302-57-8
Amlexanox( AA 673 | CHX 3673 | Elics )
Catalog No. M15611 CAS No. 68302-57-8
Amlexanox (AA673; CHX3673) is a specific inhibitor of IKKε and TBK1; inhibition of IKKε and TBK1 activity as determined by MBP phosphorylation showing an IC50 of approximately 1–2 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 48 | In Stock |
|
| 5MG | 30 | In Stock |
|
| 25MG | 52 | In Stock |
|
| 50MG | 73 | In Stock |
|
| 100MG | 90 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 217 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAmlexanox
-
NoteResearch use only, not for human use.
-
Brief DescriptionAmlexanox (AA673; CHX3673) is a specific inhibitor of IKKε and TBK1; inhibition of IKKε and TBK1 activity as determined by MBP phosphorylation showing an IC50 of approximately 1–2 μM.
-
DescriptionAmlexanox (AA673; CHX3673) is a specific inhibitor of IKKε and TBK1; inhibition of IKKε and TBK1 activity as determined by MBP phosphorylation showing an IC50 of approximately 1–2 μM.
-
In Vitro——
-
In Vivo——
-
SynonymsAA 673 | CHX 3673 | Elics
-
PathwayAngiogenesis
-
TargetFGFR
-
RecptorFGFR1| IL-3| Protein S100-P
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number68302-57-8
-
Formula Weight298.29
-
Molecular FormulaC16H14N2O4
-
Purity>98% (HPLC)
-
SolubilityDMSO: 100 mM
-
SMILESCC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N
-
Chemical Name2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shishibori T, et al. Biochem J. 1999 Mar 15;338 ( Pt 3):583-9.
molnova catalog
related products
-
hnps-PLA Inhibitor
Hnps-PLA Inhibitor is an inhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).
-
Dovitinib lactate
A novel, multitargeted RTK inhibitor of class III, IV, and V RTKs.
-
Vofatamab
Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.
